FUSOGENIX
PIPELINE
ABOUT
NEWS
CONTACT
News & Publications
June 7, 2022
Press Release: Entos Expands R&D Operations into the US
Published by:
Perrin Beatty
March 3, 2022
Press Release: Entos Announces Senior Leadership Appointments to Executive Team
Published by:
Perrin Beatty
January 5, 2022
Press Release: Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications
Published by:
Perrin Beatty
December 1, 2021
Press Conference: Entos to receive $15.5M from Alberta gov't for Edmonton vaccine manufacturing facility
Published by:
Perrin H Beatty
November 16, 2021
Press Release: BioAlberta Recognizes Entos Pharmaceuticals with 2020 Company of the Year Achievement Award
Published by:
Perrin Beatty
November 15, 2021
Press Release: Entos Enters Agreement with BioMarin to Formulate Product Candidates Incorporating Fusogenix PLVs
Published by:
Perrin Beatty
September 7, 2021
Press Release: Entos’ COVID-19 DNA Vaccine Candidate Approved for Phase 2 Clinical Trial in South Africa
Published by:
Perrin Beatty
July 7, 2021
Press Release: Canadian Companies Entos Pharmaceuticals and Montrium Join Forces to Drive Clinical Innovation
Published by:
Perrin Beatty
May 18, 2021
Press Release: Recruitment Update for the Phase 1 Clinical Trial of Entos’ Made in Canada DNA Vaccine for COVID-19
Published by:
Perrin Beatty
April 15, 2021
April 15 Marks Start of Phase I trial of Entos' COVID-19 DNA Vaccine with First Recruits
Published by:
Perrin Beatty
March 18, 2020
Press Release: Entos Pharmaceuticals Is Developing a DNA Vaccine Against COVID-19 Using Its Fusogenix Nanomedicine Platform
Published by:
Entos Pharmaceuticals
December 20, 2019
HICKS ON BIZ: The University of Alberta’s next big thing
Published by:
Graham Hicks
November 1, 2018
Entos Pharmaceuticals joins JLABS San Diego
Published by:
Entos Pharmaceuticals
July 2, 2018
Entos awarded entry into the Merck Invention Accelerator
Published by:
Entos Pharmaceuticals
March 30, 2018
Entos and Oisin Bio Announce Fusogenix License for SENSOlytics™
Published by:
Entos Pharmaceuticals
June 26, 2018
Entos and Oisin Bio Launch OncoSenX: A Spinoff Company Targeting Cancer
Published by:
John D. Lewis, PhD
November 13, 2018
Precision Nanosystems and Entos sign license agreement
Published by:
PRESS RELEASE (Precision NanoSystems)
Entos Pharmaceuticals
33 St James's Square
London, UK, SW1Y 4JS
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6
3040 Science Park Road
San Diego, CA 92121
General Contact
Tel: 1-800-727-0884
Email:
info@entospharma.com
Investor Contact
Email:
info@entospharma.com
Media Contact
Email:
media@entospharma.com
Name
Email Address
Company Name
Message
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.